Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan and Chairman John Martin will step down as soon as the end of the year, ending a nearly 30-year run at the U.S. biotech company for both men. Shares of Gilead, which also announced higher-than-expected second quarter profit, fell more than 1.6 percent in extended trading. It said the board is launching a search for a CEO to replace Milligan, who plans to leave at year-end. …read more
Source:: Yahoo Finance
